[Hyperlipoproteineumia in HIV patients undergoing antiretroviral  therapy: which risk is greater--pancreatitis or coronary disease?].
Koch
C A
CA
Wolkersdoerfer
G
G
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000188:drug therapy*; D000208:Acute Disease; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D002219:Carbamates; D003327:Coronary Disease / Q000139:chemically induced*; D015224:Dideoxynucleosides / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005663:Furans; D017320:HIV Protease Inhibitors / Q000009:adverse effects*; D006509:Hepatitis B / Q000150:complications; D006801:Humans; D006951:Hyperlipoproteinemias / Q000150:complications*; D008297:Male; D008875:Middle Aged; D010195:Pancreatitis / Q000139:chemically induced*; D012307:Risk Factors; D019438:Ritonavir / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D000099227:Abacavir
D019380:Anti-HIV Agents; D002219:Carbamates; D015224:Dideoxynucleosides; D005663:Furans; D017320:HIV Protease Inhibitors; D019438:Ritonavir; D013449:Sulfonamides; D000099227:Abacavir; C095108:amprenavir